Log in or register to see all Alerts
New HTA Decisions in England
November 2018
Drug name
XELJANZ® (tofacitinib)
Company
Pfizer
Decision date
28/11/2018
Therapeutic area
Digestive tract conditions
Therapeutic sub area
Inflammatory bowel disease
Decision
Recommended
Indication
For treating moderately to severely active ulcerative colitis in adults when conventional therapy or a biological agent cannot be tolerated or the disease has responded inadequately or lost response to treatment
Decision Detail
It is recommended only if the company provides tofacitinib with the discount agreed in the commercial arrangement
Summary
Clinical evidence from the OCTAVE trials showed that tofacitinib is more effective than placebo for induction and maintenance treatment of moderate-to-severe disease, regardless of whether TNF-alpha inhibitors have been taken previously. For patients who had not had a TNF-alpha inhibitor, tofacitinib was shown to be more effective than adalimumab and golimumab as maintenance treatment. For those who had had a TNF-alpha inhibitor, tofacitinib was shown to be more effective than adalimumab as induction treatment. The committee considered tofacitinib a cost-effective treatment due to the health-related benefits and costs compared with conventional therapy and biologicals. Tofacitinib could therefore be recommended as a treatment for moderately to severely active ulcerative colitis in adults whose disease has responded inadequately to, or who cannot tolerate, conventional or biological therapy.